Long-Term Debt: The sum of all long term debt fields.
Theravance Biopharma, Inc. (TBPH) Long-Term Debt data is not available for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$17.70M |
|
$-4.93M |
|
-- |
|
$17.70M |
|
$27.18M |
|
$-9.48M |
|
$3.01M |
|
$-6.47M |
|
$-6.47M |
|
$-4.93M |
|
$-4.93M |
|
$-4.93M |
|
$-4.93M |
|
$-9.48M |
|
$-9.70M |
|
51.28M |
|
51.28M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$417.63M |
|
$5.54M |
|
$54.68M |
|
$472.31M |
|
$31.77M |
|
|
Long-Term Debt |
-- |
$149.94M |
|
$181.72M |
|
$290.59M |
|
$290.59M |
|
$290.59M |
|
51.52M |
|
| Cash Flow Statement Financials | |
$73.28M |
|
$52.59M |
|
$-5.58M |
|
$168.64M |
|
$288.94M |
|
$120.30M |
|
$4.50M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-53.58% |
|
-53.58% |
|
-- |
|
-36.56% |
|
-27.87% |
|
$73.28M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
1.14 |
|
79.25 |
|
-1.70% |
|
-1.70% |
|
-1.04% |
|
-1.70% |
|
$5.64 |
|
$1.43 |
|
$1.43 |
|